DexCom (DXCM) Stock Price & Analysis

DXCM$82.12+0.73 +0.90%
Medical - DevicesLarge CapGrowth StockHigh Quality
Compare
Market cap$30.63BEnterprise value$33.43BRevenue (TTM)$5.10BMarket positionTop 25%

Score

62
Neutral
Value
37
Quality
80
Growth
68

AI Analysis

Snapshot

DexCom looks like a quality compounder first — Quality 80/100 and an overall 62/100. Under the hood: P/E 34.2, about 60% below its own multi-year median, plus revenue compounding ~17% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

37
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

68
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

80
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

DexCom, Inc. (DXCM) last printed $82.12. Equity value is $30.63B. Trailing earnings multiple 31.36. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$573.3M$718.5M$1.03B$1.48B$1.93B$2.45B$2.91B$3.62B$4.03B$4.66B

About

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

DexCom (DXCM) Stock Price & Analysis

DXCM price $82.12 +0.73 +0.90%

Ticker
DXCM
Price
$82.12
Change
+0.73 +0.90%
Market cap
$30.63B
P/E
31.36
Forward P/E
28.30
Dividend yield
0.00%
Beta
1.44
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
62
Value
37
Quality
80
Growth
68

Stocklytics score rationale: value 37, quality 80, growth 68.

AI Score 75. DexCom, Inc. has a strong market presence with a market cap of approximately $32.99 billion and a solid gross profit margin of about 63.4%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener